Angiotensin II (A1042): Technical Guidance for Experimental Use

What This Product Solves

Angiotensin II (A1042) is an octapeptide hormone integral for experimentally modeling key cardiovascular pathologies. Its primary value lies in reproducibly inducing vasoconstriction and activating G protein-coupled receptor (GPCR) pathways in vascular smooth muscle cells. Researchers use this reagent to:

• Interrogate molecular mechanisms in hypertension mechanism studies.
• Model vascular smooth muscle cell hypertrophy and assess downstream signaling.
• Induce cardiovascular remodeling and inflammatory responses in animal models.
• Establish abdominal aortic aneurysm models for studying vascular injury and repair.

Because of its well-defined sequence (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) and robust pharmacological properties, Angiotensin II enables controlled, repeatable experiments in both cell-based and in vivo contexts. It is not intended for clinical, diagnostic, or therapeutic use. For product specifications, see Angiotensin II at APExBIO.

Protocol Parameters

• Preparation of Stock Solution | ≥10 mM in sterile water | All experimental setups | Ensures high solubility and accurate dosing; avoid ethanol due to insolubility | product dossier
• Cell Culture Treatment | 100 nM for 4 hours | Stimulation of NADH/NADPH oxidase in vascular smooth muscle cells | Benchmarked for oxidative stress and hypertrophy studies in vitro | product dossier
• In Vivo Model Administration | 500–1000 ng/min/kg via subcutaneous minipump, up to 28 days | Induction of hypertension or abdominal aortic aneurysm in rodents | Mimics pathophysiological Angiotensin II exposure for vascular remodeling research | product dossier
• Storage | Aliquoted stocks at -80°C (months); desiccated powder at -20°C | Long-term reagent integrity | Minimizes freeze-thaw cycles and degradation | product dossier
• Working Solution Stability | Use prepared solutions promptly; avoid prolonged storage | All applications | Prevents decline in peptide activity and experimental variability | product dossier

Workflow Setup and QC Checklist

1. Reagent Handling: Weigh Angiotensin II powder rapidly in a desiccated environment to prevent moisture absorption. Use calibrated balances and sterile tools.
2. Stock Solution Preparation: Dissolve at ≥234.6 mg/mL in DMSO or ≥76.6 mg/mL in water. Vortex gently; avoid sonication to prevent peptide damage.
3. Aliquoting: Dispense into single-use aliquots to limit freeze-thaw cycles. Label each aliquot with concentration, date, and storage temperature.
4. Storage Controls: Store aliquots at -80°C for months, or keep desiccated powder at -20°C. Avoid repeated thawing.
5. Application-Specific Dosing: For cell models, dilute to final working concentrations immediately before use. For animal infusion, check minipump calibration and solution clarity.
6. QC Confirmation: Confirm peptide identity and purity via mass spectrometry or HPLC where possible. Routinely inspect for precipitation or discoloration.
7. Documentation: Record batch numbers, preparation logs, and run negative controls in all experiments.

Common Failure Modes and Fixes

• Precipitation in Working Solution: If precipitation occurs, verify solvent type (avoid ethanol), adjust to recommended concentrations, and gently re-vortex. Discard if insoluble.
• Loss of Activity Over Time: Use freshly prepared working solutions. If activity declines, check storage conditions; discard any solutions stored at room temperature or subjected to multiple freeze-thaw cycles.
• Batch-to-Batch Variability: Use the same lot for all experiments in a study when possible and document batch information. Conduct preliminary titration for each new batch.
• Inconsistent In Vivo Delivery: Confirm minipump function and ensure the solution remains clear. Inspect for leaks or blockages before and during animal studies.
• Cell Toxicity at High Concentration: If cytotoxicity is observed, verify dosing accuracy and titrate concentrations downward. Always include vehicle-only controls to distinguish peptide-specific effects.

Scope and Limitations

Angiotensin II (A1042) is formulated for research use only, specifically in mechanistic investigations of cardiovascular remodeling, vascular smooth muscle cell hypertrophy, and hypertension in cell and rodent systems. Its utility is defined by experimentally controlled dosing and well-characterized receptor activation. The product should not be used for diagnostic, therapeutic, or human applications.

Limitations include:

• Not suitable for clinical/diagnostic workflows.
• Stability is limited in solution; long-term storage should be in powder form at recommended temperatures.
• Results may vary based on experimental design, animal strain, and cell type. Empirical optimization is advised.

Conclusion

Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is a critical reagent for dissecting vascular signaling and remodeling mechanisms. Its defined solubility and dosing parameters enable reproducible hypertension and vascular injury models, provided workflow controls are rigorously observed. For detailed product information and ordering, visit Angiotensin II at APExBIO.

For additional benchmarks and mechanistic context, see the internal article Angiotensin II (A1042): Potent Vasopressor and GPCR Agonist, which details molecular actions and workflow integration. Protocol design and troubleshooting strategies for hypertension and vascular remodeling research are discussed in Angiotensin II in Hypertension Research: Protocols & Innovations.